The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

Dear Quentin,  I have two sisters who have developed Alzheimer’s disease. My younger sister is actually more severely ...

Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

A brain region affected very early in Alzheimer's disease may explain why some aging people are at greater risk of financial exploitation. That is the key finding of our new study, published in the ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a new study.

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...